Navigation Links
Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer
Date:3/24/2017

WESTLAKE VILLAGE, Calif., March 24, 2017 /PRNewswire/ -- Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage medical dermatology and aesthetics company, today announced that Richard Peterson will join the company as Chief Financial Officer, effective March 24.  

Peterson, who brings more than two decades of global financial experience, will succeed John Smither, who is retiring at the end of April but will continue to serve Sienna in an advisory capacity. Peterson joins Sienna from Novan, Inc., where he served as Chief Financial Officer for the pharmaceutical dermatology company. Previously, he was the Chief Financial Officer and Treasurer of Medicis Pharmaceutical Corporation until the company's acquisition in 2012 by Valeant Pharmaceuticals International, Inc., for $2.6 billion.

"We are pleased to welcome Ric to Sienna and look forward to his contributions as we advance our robust and diversified pipeline of topical biotech products," said Frederick C. Beddingfield III, M.D., Ph.D., Sienna's President and Chief Executive Officer. "Ric is an accomplished financial leader with a proven track record of creating value for medical dermatology and aesthetic companies that develop and market industry-leading products."

During Peterson's tenure at Medicis, the company achieved significant growth in revenue and profitability with a portfolio of top-selling medical and aesthetic products including SOLODYN® for acne and Restylane® and Dysport® for the treatment of facial wrinkles. Prior to Medicis, Peterson was a Senior Financial Auditor with PricewaterhouseCoopers. He holds a Bachelor of Science in accountancy from Arizona State University.

"I am delighted to join the Sienna team at such an exciting time for the company," Peterson said. "Sienna is poised, with innovative topical platform technologies, to address significant unmet needs and fundamentally change the treatment of dermal inflammation and aesthetic skin conditions, and I am eager to contribute to the company's success."

Sienna is developing first-in-class late-stage clinical candidates to create targeted safe and effective topical therapies that treat conditions such as psoriasis, atopic dermatitis, pruritus, acne vulgaris and unwanted light-pigmented hair with limited systemic exposure.

"I would like to recognize and thank John Smither, who has worked tirelessly to help establish Sienna and expand our portfolio," Dr. Beddingfield said. "John has been instrumental in securing financing and building a stellar finance team that sets Sienna up for success as we move forward. We are pleased that we will continue to benefit from his counsel."

About Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals, Inc. is a medical dermatology and aesthetics company focused on developing safe and effective targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Sienna is led by a team of accomplished scientists, clinicians and business leaders who have developed and commercialized leading global brands in dermatology and aesthetics. Sienna is building an innovative, diversified pipeline to address unmet needs in medical dermatology and aesthetics. The company's investors include: ARCH Venture Partners; Partner Fund Management; Altitude Life Science Ventures; Venvest Capital; Two River; and several prominent medical dermatology and aesthetics industry luminaries. Find more information at www.siennabio.com.

SOLODYN® is a registered trademark of Valeant Pharmaceuticals International, Inc.; Restylane® and Dysport® are registered trademarks of Galderma.

Contact:
Ryan Irvine, Ph.D.
Vice President, Head of Medical Affairs
rirvine@siennabio.com

Investors:
Derek Cole
720.785.4497
derek.cole@IRadvisory.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/richard-peterson-joins-sienna-biopharmaceuticals-as-chief-financial-officer-300428999.html


'/>"/>
SOURCE Sienna Biopharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Longitude Capital Promotes Josh Richardson, M.D., To Managing Director
2. Cold Chain Technologies Promotes Richard Formato to Principal Technologist
3. Neuralstem Appoints Richard Daly as President and Chief Executive Officer
4. Former Senior Janssen Executive Dr. Richard C. Siegel, PhD Joins NDA Partners as a Premier Expert Consultant
5. Kiadis Pharma Appoints Dr. Vincent Brichard to its Supervisory Board
6. Richard Rubenstein, MD Selected As One Of South Floridas Top Doctors!
7. 23andMe to Create Therapeutics Group, Appoints Scientific Luminary, R&D Executive Richard Scheller, Ph.D. to Lead
8. Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund
9. Y-Prime Names Richard Gastineau Chief Operating Officer
10. Spherix Appoints Richard Cohen as Chief Financial Officer
11. Cleveland Heart Founder Dr. Charles Richardson Appointed to ReliantHeart Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2019)... (PRWEB) , ... May 29, 2019 , ... For many ... the toughest forms of cancer demand breakthrough therapies. Advances in immuno-oncology have led to ... patient’s own T cells with engineered T cell receptors known as “CARs”. The CAR ...
(Date:5/31/2019)... ... May 30, 2019 , ... Object Pharma, Inc., a startup ... of Metabiologics, Inc., a globally recognized leader in the production and sale of ... to a full spectrum of botulinum neurotoxins, as well as a CDC approved ...
(Date:5/21/2019)... Ethiopia (PRWEB) , ... May 21, 2019 , ... ... Brauerei in Berlin (VLB) today officially opened the inaugural Africa Brewing Conference dedicated ... and malting industry in Africa. The event, which is supported through a partnership ...
(Date:5/14/2019)... ... May 13, 2019 , ... Leak Detection Associates (LDA), ... Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ is excited to announce the ... improve LDA’s ability to communicate directly with the marketplace; serving as a destination ...
Breaking Biology Technology:
(Date:6/13/2019)... BOSTON (PRWEB) , ... June 13, 2019 , ... ... Future of Spine & The Spine, Orthopedic and Pain Management-Driven ASC Conference in Chicago ... Hotels & Resorts 323 E. Wacker Dr. Chicago, IL in the 3rd floor Ticino ...
(Date:6/11/2019)... ... June 12, 2019 , ... With a rapidly growing ... leverage the Geneious Biologics platform as a premium hub for bioinformatics and computer ... says: “The Geneious team has done an excellent job accommodating our specific data, ...
(Date:6/6/2019)... ... June 05, 2019 , ... MedTech Breakthrough , ... health and medical technology market, announced that it has selected Medacta International’s MySpine® ... award in the 2019 MedTech Breakthrough Awards program. , Medacta® ...
Breaking Biology News(10 mins):